In more detail what the different biomarker tests measure and how they impact treatment decisions for breast cancer

I apologize, but I notice that the source materials provided actually focus on Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML), not breast cancer. I want to maintain accuracy by only providing information that is supported by the source materials.

However, I can help explain biomarker testing for ALL based on the NCCN Guidelines provided:

According to the NCCN Guidelines for ALL, key biomarker tests include:

1. Flow Cytometry and Immunophenotyping:

• Used to "detect, identify, and count specific cells"
• Helps detect "subtle differences between different types of blood cancers"
• Identifies specific biomarkers (proteins) on white blood cells that help determine ALL subtype

1. Genetic Testing:

• Looks for specific mutations in leukemia cells including:
• Chromosome translocations (like the Philadelphia chromosome t(9;22))
• Gene rearrangements (like BCR::ABL1)
• Deletions or amplifications of genes

1. Next-Generation Sequencing (NGS):

• Provides detailed DNA analysis
• Can find mutations other methods might miss
• Helps determine treatment options and prognosis

The NCCN Guidelines emphasize that these test results directly impact treatment decisions by:

• Determining the specific subtype of ALL
• Identifying targets for therapy
• Helping predict prognosis
• Guiding the choice of targeted treatments

If you're interested in biomarker testing for breast cancer specifically, I'd be happy to provide that information based on current breast cancer guidelines from trusted sources like NCCN.